Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 6/20 | 0.44 |
| ▸ | CNR1 | P21554 | 4/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2024342 | 0.99 | KDM4E (0.49) | KDM4EKMT2AL3MBTL1CNR2CNR1 | |
| SCHEMBL2536987 | 0.99 | KDM4E (0.49) | KDM4EKMT2AL3MBTL1CNR2CNR1 | |
| SCHEMBL3740930 | 0.99 | KDM4E (0.49) | KDM4EKMT2AL3MBTL1CNR2CNR1 | |
| SCHEMBL8015861 | 0.99 | KDM4E (0.49) | KDM4EKMT2AL3MBTL1CNR2CNR1 | |
| SCHEMBL451183 | 0.99 | KDM4E (0.49) | KDM4EKMT2AL3MBTL1CNR2CNR1 | |
| SCHEMBL1826965 | 0.99 | KDM4E (0.49) | KDM4EKMT2AL3MBTL1CNR2CNR1 | |
| SCHEMBL2028355 | 0.99 | KDM4E (0.49) | KDM4EKMT2AL3MBTL1CNR2CNR1 | |
| SCHEMBL5357939 | 0.99 | KDM4E (0.49) | KDM4EKMT2AL3MBTL1CNR2CNR1 | |
| SCHEMBL6842064 | 0.95 | ALOX5 (0.44) | KDM4EKMT2AL3MBTL1ALOX5CYP2C9 | |
| SCHEMBL5351493 | 0.91 | FAAH (0.45) | KDM4EKMT2AL3MBTL1CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | claimed |
| US-4308348-A | SALMONELLA, SERRATIA, PROTEUS, PROVIDENCIA | LABORATOIRE DE RECHERCHE API (FR) | 1981-12-29 | — | — | US | claimed |
| CN-106471119-A | Compositions and methods for increasing yield | 诺华股份有限公司 | 2017-03-01 | — | — | CN | disclosed |
| CN-101417129-A | Gabapentin analogues for fibromyalgia and other related disorders | WARNER LAMBERT CO (US) | 2009-04-29 | — | — | CN | disclosed |
| CN-100482645-C | Methods of reversing and preventing cardiovascular pathologies | ATHEROGENICS INC (US) | 2009-04-29 | — | — | CN | disclosed |
| CN-100430048-C | Alpha-2-delta ligands for the treatment of lower urinary tract symptoms | WARNER LAMBERT CO (US) | 2008-11-05 | — | — | CN | disclosed |
| EP-1748984-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| CN-1874758-A | Compositions comprising fenofibrate and pravastatin | LIFECYCLE PHARMA AS (DK) | 2006-12-06 | — | — | CN | disclosed |
| CN-1832957-A | Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereofin treating or preventing a variety of diseases and conditions | FORBES MEDI TECH INC (CA) | 2006-09-13 | — | — | CN | disclosed |
| CN-1720029-A | Alpha-2-delta ligands for the treatment of lower urinary tract symptoms | WARNER LAMBERT CO (US) | 2006-01-11 | — | — | CN | disclosed |
| WO-2005110987-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
| CN-1612855-A | Method for reversing and preventing cardiovascular disease | ATHEROGENICS INC (US) | 2005-05-04 | — | — | CN | disclosed |
| US-4308348-A | SALMONELLA, SERRATIA, PROTEUS, PROVIDENCIA | LABORATOIRE DE RECHERCHE API (FR) | 1981-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | KDM4E 2227/4885KMT2A 1384/4885L3MBTL1 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.